AKL Research and Development
News
APPA reduces senescence & reactive oxygen species production
New data presented at the European League against Rheumatism (EULAR) demonstrates that APPA reduces the number of senescent chondrocytes, and inhibits ROS production in human articular chondrocytes. Today AKL Research & Development unveils new data at the Virtual European Congress of Rheumatology (EULAR) 2021 (June 2-5). Findings from the study indicate our investigational oral osteoarthritis […]
Read More
New studies suggests APPA protects against joint damage
Today sees the unveiling of new data at the Osteoarthritis Research Society International (OARSI) Virtual World Congress (April 29 – May 1) indicating investigational oral osteoarthritis (OA) drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease. Read full press release. Characterizing the effect of […]
Read More
APPA Phase II human study completes ahead of schedule
Despite Covid, the Phase II 150-patient placebo-controlled Human Efficacy Study of APPA in osteoarthritis of the knee has completed patient recruitment a month ahead of schedule and the last patient to enter the study completed their treatment on 16th April.
Read More
How close are disease‐modifying drugs for OA?
Progress in the development of disease‐modifying drugs for osteoarthritis has been hampered by a lack of understanding of the pathogenesis of the disease and how it differs from rheumatoid arthritis. However, more recent research in this field has identified several promising therapeutic targets. The symptoms of osteoarthritis, the most common joint disorder, typically emerge at […]
Read More